

May 18, 2026

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC.

Kindly find attached media release which is self- explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial

Elmwood Park, New Jersey, May 18, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch¹ of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark’s Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC.

According to IQVIA[®] sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market² achieved annual sales of approximately \$37.9 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark’s continued commitment to expanding access to quality, affordable medicines in the U.S. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients.”

¹Glenmark’s Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is only approved for the indication(s) listed in Glenmark’s approved label.

²Market includes brand and all available therapeutic equivalents. Note: IQVIA[®] data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.

*IQVIA[®] National Sales Perspectives: Retail & Non-Retail, March 2026.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact

India	United States
<p>Akhila Natarajan mediarelations@glenmarkpharma.com +91 22 4018 9999</p> <p>Adfactors PR glenmark.ihcp@adfactorspr.com +91 9535635461</p>	<p>Akhila Natarajan mediarelations@glenmarkpharma.com</p> <p>Danielle Hagen danielle@nahigianstrategies.com 202-365-6112</p>